Harpoon Therapeutics Inc
Change company Symbol lookup
Select an option...
HARP Harpoon Therapeutics Inc
VIRC Virco Mfg Corp
RVLP RVL Pharmaceuticals PLC
TRGP Targa Resources Corp
RCRT Recruiter.Com Group Inc
VGAS Verde Clean Fuels Inc
DHHC DiamondHead Holdings Corp
EJH E-Home Household Service Holdings Ltd
FLGC Flora Growth Corp
HL Hecla Mining Co
Go

Health Care : Biotechnology | Small Cap Value
Company profile

Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company. The Company is engaged in the developing a T cell engager that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. It is developing a pipeline of T cell engagers using its TriTACs, focused on the treatment of solid tumors and hematologic malignancies. It has also nominated its clinical candidate using its ProTriTAC platform, a prodrug version of its TriTAC platform, designed to expand the target space for T cell engagers and bring the benefits of TriTACs to the patients. The Company’s TriTAC product candidates include HPN328, HPN217 and HPN536. The Company’s ProTriTAC product candidate include HPN601. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells.

Closing Price
$0.6725
Day's Change
-0.0145 (-2.11%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.6997
Day's Low
0.631
Volume
(Average)
Volume:
344,365

10-day average volume:
328,263
344,365

CTXS, GAIA & DAKT Class Action Reminders: Bronstein, Gewirtz & Grossman, LLC, A Successful Firm, Reminds Investors of Deadlines and to Actively Participate

11:00 am ET January 25, 2023 (Accesswire) Print

NEW YORK, NY / ACCESSWIRE / January 25, 2023 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Bronstein, Gewirtz and Grossman, LLC, Wednesday, January 25, 2023, Press release picture

Citrix Systems, Inc. (NASDAQ:CTXS)

Class Period: Citrix common stock held as of the close of business on September 30, 2022 ("Class Period") through current

Deadline: February 13, 2023

For more info:www.bgandg.com/ctxs.

The complaint alleges the Board deliberately used false projections to conceal the true value of Citrix from Citrix shareholders and thereby secured the approval of such shareholders to sell Citrix to Vista Equity Partners ("Vista") and Elliott Investment Management L.P. ("Elliott") for the inadequate and unfair price of $104.00 per share in cash ("Merger Consideration"), pursuant to a merger ("Merger") under which Citrix became a wholly-owned subsidiary of TIBCO Software, Inc. ("TIBCO"), a portfolio company of Vista. The Complaint continues to allege that the false and misleading Proxy authorized by defendants caused the consummation of the Merger at an unfair price per share that did not adequately value Citrix and thus caused economic harm to Citrix, who were forced to sell their shares to Elliott and Citrix at an unfair and inadequate price.

Gaia, Inc. (NASDAQ:GAIA)

Class Period: December 26, 2017 - November 7, 2022

Deadline: February 21, 2023

For more info:www.bgandg.com/gaia.

The complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose, among other things, that: (1) the Company's first quarter 2019 subscriber count was overstated; (2) the Company lacked adequate internal controls; (3) as a result, defendants had a heightened risk of regularly scrutiny and ultimately subject to an SEC investigation and action; and (4) as a result of the foregoing, defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the truth emerged, the lawsuit claims that investors suffered damages.

Daktronics, Inc. (NASDAQ:DAKT)

Class Period: March 10, 2022 - December 6, 2022

Deadline: February 21, 2023

For more info:www.bgandg.com/dakt.

The complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that the Company was experiencing challenges that increased costs, including supply chain disruptions, that impacted Daktronics' ability to fund inventory levels and operations; (2) that, as a result, it was probable that some portion of the Company's deferred tax assets would not be realized; (3) that as a result, Daktronics was reasonably likely to record a material valuation allowance to its deferred tax assets; (4) that there were material weaknesses in the Company's internal controls over financial reporting related to income taxes; (5) that the foregoing presented liquidity concerns and there was substantial doubt as to the Company's ability to continue as a going concern; (6) as a result, Defendants' statements about its business, operations, and prospects were materially false and misleading and/or lacked reasonable basis at all relevant times.

Contact:

Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Yael Nathanson

212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC





View source version on accesswire.com:

https://www.accesswire.com/733852/CTXS-GAIA-DAKT-Class-Action-Reminders-Bronstein-Gewirtz-Grossman-LLC-A-Successful-Firm-Reminds-Investors-of-Deadlines-and-to-Actively-Participate



comtex tracking

COMTEX_423274268/2457/2023-01-25T11:00:53

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.